283 related articles for article (PubMed ID: 19773430)
1. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.
Luistro L; He W; Smith M; Packman K; Vilenchik M; Carvajal D; Roberts J; Cai J; Berkofsky-Fessler W; Hilton H; Linn M; Flohr A; Jakob-Røtne R; Jacobsen H; Glenn K; Heimbrook D; Boylan JF
Cancer Res; 2009 Oct; 69(19):7672-80. PubMed ID: 19773430
[TBL] [Abstract][Full Text] [Related]
2. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
Kolb EA; Gorlick R; Keir ST; Maris JM; Lock R; Carol H; Kurmasheva RT; Reynolds CP; Kang MH; Wu J; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2012 May; 58(5):815-8. PubMed ID: 22052798
[TBL] [Abstract][Full Text] [Related]
3. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.
Huynh C; Poliseno L; Segura MF; Medicherla R; Haimovic A; Menendez S; Shang S; Pavlick A; Shao Y; Darvishian F; Boylan JF; Osman I; Hernando E
PLoS One; 2011; 6(9):e25264. PubMed ID: 21980408
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.
Debeb BG; Cohen EN; Boley K; Freiter EM; Li L; Robertson FM; Reuben JM; Cristofanilli M; Buchholz TA; Woodward WA
Breast Cancer Res Treat; 2012 Jul; 134(2):495-510. PubMed ID: 22547109
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Tolcher AW; Messersmith WA; Mikulski SM; Papadopoulos KP; Kwak EL; Gibbon DG; Patnaik A; Falchook GS; Dasari A; Shapiro GI; Boylan JF; Xu ZX; Wang K; Koehler A; Song J; Middleton SA; Deutsch J; Demario M; Kurzrock R; Wheler JJ
J Clin Oncol; 2012 Jul; 30(19):2348-53. PubMed ID: 22529266
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.
Dantas-Barbosa C; Bergthold G; Daudigeos-Dubus E; Blockus H; Boylan JF; Ferreira C; Puget S; Abely M; Vassal G; Grill J; Geoerger B
Anticancer Drugs; 2015 Mar; 26(3):272-83. PubMed ID: 25486598
[TBL] [Abstract][Full Text] [Related]
7. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.
He W; Luistro L; Carvajal D; Smith M; Nevins T; Yin X; Cai J; Higgins B; Kolinsky K; Rizzo C; Packman K; Heimbrook D; Boylan JF
Mol Oncol; 2011 Jun; 5(3):292-301. PubMed ID: 21315665
[TBL] [Abstract][Full Text] [Related]
8. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
Wang L; Dai G; Yang J; Wu W; Zhang W
Med Sci Monit; 2018 Jun; 24():4046-4053. PubMed ID: 29899322
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
[TBL] [Abstract][Full Text] [Related]
10. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
[TBL] [Abstract][Full Text] [Related]
11. An accessible pharmacodynamic transcriptional biomarker for notch target engagement.
Tanis KQ; Podtelezhnikov AA; Blackman SC; Hing J; Railkar RA; Lunceford J; Klappenbach JA; Wei B; Harman A; Camargo LM; Shah S; Finney EM; Hardwick JS; Loboda A; Watters J; Bergstrom DA; Demuth T; Herman GA; Strack PR; Iannone R
Clin Pharmacol Ther; 2016 Apr; 99(4):370-80. PubMed ID: 26765077
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
Lee SM; Moon J; Redman BG; Chidiac T; Flaherty LE; Zha Y; Othus M; Ribas A; Sondak VK; Gajewski TF; Margolin KA
Cancer; 2015 Feb; 121(3):432-440. PubMed ID: 25250858
[TBL] [Abstract][Full Text] [Related]
13. Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment.
Pisklakova A; Grigson E; Ozerova M; Chen F; Sullivan DM; Nefedova Y
Cancer Biol Ther; 2016 May; 17(5):477-85. PubMed ID: 26934342
[TBL] [Abstract][Full Text] [Related]
14. Rethinking Gamma-secretase Inhibitors for Treatment of Non-small-Cell Lung Cancer: Is Notch the Target?
Pine SR
Clin Cancer Res; 2018 Dec; 24(24):6136-6141. PubMed ID: 30104200
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Notch and TGF-β signaling pathways to prevent retinal fibrosis
Fan J; Shen W; Lee SR; Mathai AE; Zhang R; Xu G; Gillies MC
Theranostics; 2020; 10(18):7956-7973. PubMed ID: 32724452
[No Abstract] [Full Text] [Related]
16. γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer.
Mizugaki H; Sakakibara-Konishi J; Ikezawa Y; Kikuchi J; Kikuchi E; Oizumi S; Dang TP; Nishimura M
Br J Cancer; 2012 Jun; 106(12):1953-9. PubMed ID: 22596234
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
Diaz-Padilla I; Wilson MK; Clarke BA; Hirte HW; Welch SA; Mackay HJ; Biagi JJ; Reedijk M; Weberpals JI; Fleming GF; Wang L; Liu G; Zhou C; Blattler C; Ivy SP; Oza AM
Gynecol Oncol; 2015 May; 137(2):216-22. PubMed ID: 25769658
[TBL] [Abstract][Full Text] [Related]
18. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.
Yang T; Arslanova D; Gu Y; Augelli-Szafran C; Xia W
Mol Brain; 2008 Nov; 1():15. PubMed ID: 18983676
[TBL] [Abstract][Full Text] [Related]
19. PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.
Nair JS; Sheikh T; Ho AL; Schwartz GK
Anticancer Res; 2013 Apr; 33(4):1307-16. PubMed ID: 23564767
[TBL] [Abstract][Full Text] [Related]
20. GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.
Meng X; Matlawska-Wasowska K; Girodon F; Mazel T; Willman CL; Atlas S; Chen IM; Harvey RC; Hunger SP; Ness SA; Winter SS; Wilson BS
Leukemia; 2011 Jul; 25(7):1135-46. PubMed ID: 21494254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
